Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus MONISTAT 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus MONISTAT 7.
FULVICIN P/G 330 vs MONISTAT 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity.
330 mg orally once daily with fatty meal to enhance absorption.
Intravaginal administration of 100 mg miconazole nitrate suppository once daily at bedtime for 7 days.
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Terminal elimination half-life is approximately 24-30 hours following intravaginal administration; clinical significance: supports once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Primarily via feces (approximately 87-93% of dose) as unchanged drug and metabolites; renal excretion negligible (<1%).
Category C
Category C
Antifungal
Antifungal